Genmab — Juli 2024
-
Tisotumab vedotin effective in recurrent cervical cancer - article in Nature, can't read it all,
but anyway.. https://www.nature.com/articles/s41571-024-00929-4 -
ESMO 2024 preview – conjugates in the spotlight https://www.oncologypipeline.com/apexonco/node/734 rinatabart
-
Epcoritamab vs SoC (SCHOLAR-5 cohort) in patients with R/R FL https://www.youtube.com/watch?v=SQgjUgIJU4E
-
Tisotumab Vedotin Continues to Show Survival Benefits in Recurrent Cervical Cancer https://www.targetedonc.com/view/tisotumab-vedotin-continues-to-show-survival-benefits-in-recurrent-cervical-cancer
-
Thanks E L.
-
from the Morningstart report on Novartis: several other drugs continue to post rapid gains. In particular, multiple
sclerosis drug Kesimpta (up 65%) holds the potential to exceed management's peak annual sales
guidance of $4 billion based on leading efficacy and convenient dosing -
Topo-1 and FRα: Key Focus Areas and Major Collaborations in ADC Research – Part I https://www.geneonline.com/topo-1-and-frα-key-focus-areas-and-major-collaborations-in-adc-research-part-i/
-
Genmab i teknisk udbrud op gennem 50 dages MA, plus 12 % på tre uger https://ugebrev.dk/flashnews/genmab-i-teknisk-udbrud-op-gennem-50-dages-ma-plus-12-paa-tre-uger/
-
Et spørgsmål til teknikerne..... Hvornår gør et gap luk sig gældende?.... Tænker at nu har vi set Genmab forhåbentlig have lavet en vending/bund i omkring kurs 1700.... Nu da aktien jo egentlig ikke har dannet en bund i dette niveau, siger teknikken så at vi skal have lukket det gap, førend en eventuel optur kan fortsætte?
-
some gaps close, some remain open forever. Some 'runaway gaps' can actually run away from the gap very fast. So I don't trade them as such. The open and close points of the gap can often be seen as resistance or support though, i think that is much more tradeable.
-
AbbVie's EPKINLY
Receives First-Ever Time-Limited Reimbursement Recommendation by Canada's Drug Agency https://finance.yahoo.com/news/abbvies-epkinly-receives-first-ever-110200465.html -
Hemab Therapeutics
@Hemab_Tx
“The whole system stops working.”This is the story of Glanzmann thrombasthenia. The transfusion of platelets – which seems like an obvious solution – is sometimes simply not an option. https://x.com/Hemab_Tx/status/1815718038802444611
-
Siden bunden er der et gap mellem den 11. og 12. Juli på 50 øre. Det blev lukket den 15. Juli. Så rent bord til fortsatte stigninger, hvis man er TA-troende
https://finance.yahoo.com/quote/GMAB.CO/chart/#eyJpbnRlcnZhbCI6ImRheSIsInBlcmlvZGljaXR5IjoxLCJjYW5kbGVXaWR0aCI6Ni40MjczNTA0MjczNTA0MjgsInZvbHVtZVVuZGVybGF5Ijp0cnVlLCJjcm9zc2hhaXIiOnRydWUsImNoYXJ0VHlwZSI6ImNhbmRsZSIsImV4dGVuZGVkIjpmYWxzZSwibWFya2V0U2Vzc2lvbnMiOnt9LCJhZ2dyZWdhdGlvblR5cGUiOiJvaGxjIiwiY2hhcnRTY2FsZSI6ImxpbmVhciIsInBhbmVscyI6
Men selvfølgelig tilfreds MA50 til en start.Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind